Post

New research · Urology
Genome biology · 23h
StudyGenome biology · 2026

Decoding 3D chromatin architecture reveals distinct enhancer classes underlying hierarchical gene regulation in prostate cancer.

Huan Cao, Zexun Wu, Baixi Ji … Suhn K Rhie
Read paper
UrologyStudy

Researchers identified 3,216 prostate cancer-specific enhancers through chromatin analysis.

Decoding 3D chromatin architecture reveals distinct enhancer classes underlying hierarchical gene regulation in prostate cancer.

Huan Cao et al. · Genome biology · 2026
Background

The transcription process is controlled by non-coding regulatory elements, more than 70% of which are putative enhancers.

3,216
Results
This many specific enhancers were found in prostate cancer cells, not normal cells.
n = 201 H3K27ac ChIP-seq datasets
More results

Ultra-high-resolution chromatin interaction profiling by Region Capture Micro-C at a representative chr6q24.1 locus reveals that these enhancers form cancer-specific, highly nested interactions with promoters that coalesce into a multi-connected hub absent in normal prostate cells.

More results

CRISPR/Cas9 perturbations of these enhancers, examined one by one, distinguish enhancer classes within the hub.

We also observe that FOXA1, a pioneer transcription factor activated in prostate cancer, directly binds to these enhancers and regulates distinct enhancer classes, leading to varying degrees of chromatin accessibility and gene expression changes.

“
Conclusion · 1 of 2

These findings suggest that enhancers function in a coordinated manner, forming multi-connected cancer-specific chromatin interaction hubs, with distinct enhancer classes contributing differently to gene regulation.

Conclusion · 2 of 2

This study advances our ability to modulate gene expression in a cell type-specific manner, opening new avenues for precision therapies.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
HR 1.87
lower muscle quality means nearly twice the risk of dying from advanced prostate cancer
Cross-sectional
71.8%
most urologists never used a standard survey to assess stent symptoms
Cohort Study
SIR 1.67
young bladder cancer survivors have a higher risk of developing second cancers compared to the general population
Cohort Study
98%
98% of patients had no significant rectocele after laparoscopic double sacrocolpopexy.
Cohort Study
OR 0.10
Beyond 4000 J/ml, the odds of reintervention are 90% lower.
Randomized Trial
hazard ratio 0·67
pirarubicin instillation led to a lower risk of recurrence compared to observation
Study
75%
experts agreed on the recommendations for managing prostate cancer recurrence
Case-control
OR = 4.23
Higher triglycerides linked to higher odds of prostate cancer (odds, not risk)